{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:30:13Z","timestamp":1778056213014,"version":"3.51.4"},"posted":{"date-parts":[[2021,11,18]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":8,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Both clinical trials and studies leveraging real-world data have repeatedly confirmed the three COVID-19 vaccines authorized for use by the Food and Drug Administration are safe and effective at preventing infection, hospitalization, and death due to COVID-19 and a recent observational study of self-reported symptoms provides support that vaccination may also reduce the probability of developing long-COVID. As part of a federated research study with the COVID-19 Patient Recovery Alliance, Arcadia.io performed a retrospective analysis of the medical history of 240,648 COVID-19-infected persons to identity factors influencing the development and progression of long-COVID. This analysis revealed that patients who received at least one dose of any of the three COVID vaccines prior to their diagnosis with COVID-19 were 7-10 times less likely to report two or more long-COVID symptoms compared to unvaccinated patients. Furthermore, unvaccinated patients who received their first COVID-19 vaccination within four weeks of SARS-CoV-2 infection were 4-6 times less likely to report multiple long-COVID symptoms, and those who received their first dose 4-8 weeks after diagnosis were 3 times less likely to report multiple long-COVID symptoms compared to those who remained unvaccinated. This relationship supports the hypothesis that COVID-19 vaccination is protective against long-COVID and that effect persists even if vaccination occurs up to 12 weeks after COVID-19 diagnosis. A critical objective of this study was hypothesis generation, and the authors intend to perform further studies to substantiate the findings and encourage other researchers to as well.<\/jats:p>","DOI":"10.1101\/2021.11.17.21263608","type":"posted-content","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T22:40:14Z","timestamp":1637275214000},"source":"Crossref","is-referenced-by-count":38,"title":["Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After"],"prefix":"10.64898","author":[{"given":"Michael A.","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan D.","family":"Luginbuhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021112000300971000_2021.11.17.21263608v1.1","unstructured":"Food and Drug Administration. COVID-19 vaccines. Silver Spring, MD: US Department of Health and Human Services; Food and Drug Administration; 2021. Accessed August 29, 2021. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines"},{"key":"2021112000300971000_2021.11.17.21263608v1.2","doi-asserted-by":"crossref","unstructured":"Antonelli M , et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet Infectious Diseases. Epub 2021 Sept 1. DOI: https:\/\/doi.org\/10.1016\/S1473-3099(21)00460-6","DOI":"10.1016\/S1473-3099(21)00460-6"},{"key":"2021112000300971000_2021.11.17.21263608v1.3","unstructured":"Katella K. Why Vaccines May Be Helping Some With Long COVID. Yale Medicine; 2021."},{"key":"2021112000300971000_2021.11.17.21263608v1.4","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services; Centers for Disease Control and Prevention; 2021. Accessed August 29, 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions"},{"key":"2021112000300971000_2021.11.17.21263608v1.5","unstructured":"COVID-19 Interoperability Alliance. COVID-19 Value Sets. Accessed from https:\/\/covid19ia.org on 4\/6\/2021 and used under a Creative Commons Attribution-NonCommercial 4.0 International License."},{"key":"2021112000300971000_2021.11.17.21263608v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3026"},{"key":"2021112000300971000_2021.11.17.21263608v1.7","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccination and SARS-CoV-2 infection: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Atlanta, GA: US Department of Health and Human Services; Centers for Disease Control and Prevention; 2021. Accessed August 29, 2021. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html#CoV-19-vaccination"},{"key":"2021112000300971000_2021.11.17.21263608v1.8","doi-asserted-by":"crossref","unstructured":"Arnold DT , Milne A , Samms E , Stadon L , Maskell NA , Hamilton FW . Are vaccines safe in patients with Long COVID? A prospective observational study. Cold Spring Harbor Laboratory Press; MedRxiv; Epub 2021. DOI: https:\/\/doi.org\/10.1101\/2021.03.11.21253225","DOI":"10.1101\/2021.03.11.21253225"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.11.17.21263608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:29:57Z","timestamp":1768487397000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.11.17.21263608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":8,"URL":"https:\/\/doi.org\/10.1101\/2021.11.17.21263608","relation":{},"subject":[],"published":{"date-parts":[[2021,11,18]]},"subtype":"preprint"}}